TBC1D10C is a selective, constitutive suppressor of the CD8 T-cell antitumor response, and the Tbc1d10c–Map3k3–NF-κB signaling axis is a viable therapeutic target to promote CD8 T-cell antitumor immunity while circumventing CD4 T cell-associated cytotoxicity and NF-κB activation in tumor cells (51). Here, MAP3K3 is linked to neoplasm.